driven by the success of Novo Nordisk’s Wegovy (semaglutide), and Eli Lilly’s Zepbound (tirzepatide). Wegovy is forecast to bring in $19.6bn in sales in 2030, with Zepbound estimated to make $ ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Eli Lilly and Company’s competing weight-loss drug, Zepbound (tirzepatide), could post over ... They were joined by RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and ...

The company has secured $410m in an oversubscribed Series A funding round, co-led by Forbion and General Atlantic, with contributions from investors such as RA Capital Management, OrbiMed, Logos ...

The financing was co-led by Frazier Life Sciences and Deep Track Capital, with Janus Henderson Investors, Logos Capital ... and Eli Lilly's Zepbound (tirzepatide), as well as future market ...

agonist azelaprag with Eli Lilly’s dual GLP-1/GIP agonist tirzepatide – already approved as Zepbound for obesity treatment. The study is due to start later this year. The Richmond, California ...

A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone shots for people with a rare genetic form of lipodystrophy that leaves patients ...

It has been a year since the launch of Zepbound (tirzepatide) for obesity, and Eli Lilly's competition with Novo Nordisk continues. “From the start, Zepbound emerged as the primary new ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...